Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effect of Quadro-Iliac Plane Block on Recovery After Laparoscopic Hysterectomy (QIPB-TLH)

11 november 2026 uppdaterad av: Betul Kozanhan, Konya Meram State Hospital

Effect of Quadro-Iliac Plane Block on Postoperative Quality of Recovery in Patients Undergoing Laparoscopic Hysterectomy: A Prospective, Randomized, Controlled Clinical Trial

This prospective, randomized, controlled clinical trial aims to evaluate the effect of an ultrasound-guided bilateral quadro-iliac plane block (QIPB) on postoperative recovery quality in patients undergoing elective total laparoscopic hysterectomy.

Studieöversikt

Status

Har inte rekryterat ännu

Detaljerad beskrivning

Total laparoscopic hysterectomy (TLH) is a minimally invasive surgical procedure; however, patients may experience postoperative pain originating from abdominal incisions, visceral manipulation, and pneumoperitoneum-related irritation. Inadequate postoperative pain management may negatively affect patient comfort, early mobilization, and overall quality of recovery. Although opioids provide effective analgesia, their use may be associated with nausea, vomiting, sedation, and other adverse effects. Therefore, multimodal and opioid-sparing analgesic strategies are important components of perioperative care.

The quadro-iliac plane block (QIPB) is an ultrasound-guided fascial plane block targeting the anatomical plane near the caudal attachment of the quadratus lumborum muscle to the iliac crest. Previous clinical studies have suggested that QIPB may improve postoperative analgesia and reduce opioid requirements in selected surgical populations. However, its effect on postoperative recovery quality following total laparoscopic hysterectomy remains to be investigated.

Studietyp

Interventionell

Inskrivning (Beräknad)

60

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Female patients aged 18 years or older.
  • Scheduled for elective total laparoscopic hysterectomy.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Body weight of at least 55 kg.
  • Ability to communicate in Turkish and reliably complete the Turkish version of the Quality of Recovery-15 questionnaire (QoR-15T).
  • Provision of written informed consent after receiving information about the study.

Exclusion Criteria:

  • Refusal to provide informed consent or withdrawal of consent.
  • Any contraindication to regional anesthesia.
  • Infection at the intended block site or anatomical conditions preventing safe needle insertion.
  • Severe hypersensitivity or contraindication to local anesthetics or standard/rescue analgesic medications specified in the study protocol.
  • Regular opioid use or opioid use disorder.
  • Regular analgesic use for chronic pain lasting longer than three months.
  • Clinically significant hepatic or renal insufficiency.
  • Pregnancy, postpartum period, or breastfeeding.
  • Cognitive or communication impairment preventing reliable completion of QoR-15T or postoperative pain assessments.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: QIPB Group

Patients will receive bilateral ultrasound-guided quadro-iliac plane blocks with 20 mL of 0.25% bupivacaine per side in addition to standard multimodal analgesia.

After surgery and before extubation, bilateral QIPB will be performed under ultrasound guidance. A total of 40 mL of 0.25% bupivacaine (20 mL per side) will be injected into the quadro-iliac fascial plane.

Andra namn:
  • QIPB
Inget ingripande: Control Group

Patients will receive standard general anesthesia and postoperative multimodal analgesia without a regional block.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Quality of Postoperative Recovery Assessed by the QoR-15T Score
Tidsram: 24 hours postoperatively

Postoperative quality of recovery will be assessed using the validated Turkish version of the 15-item Quality of Recovery questionnaire (QoR-15T). The questionnaire consists of 15 items, each scored from 0 to 10, yielding a total score ranging from 0 to 150. Higher scores indicate better quality of recovery. The primary outcome is the total QoR-15T score at 24 hours postoperatively, compared between the bilateral Quadro-Iliac Plane Block (QIPB) group and the control group.

24 hours postoperatively

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Postoperative Pain Intensity at Rest
Tidsram: PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively

Postoperative pain intensity at rest will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
Postoperative Pain Intensity During Movement or Coughing
Tidsram: PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively

Postoperative pain intensity during movement or coughing will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
Time to First Rescue Analgesia
Tidsram: Within 24 hours postoperatively

Time from admission to the post-anesthesia care unit (PACU) to the first administration of rescue analgesia will be recorded in minutes.

Within 24 hours postoperatively
Time to First Opioid Analgesia
Tidsram: Within 24 hours postoperatively

Time from admission to the post-anesthesia care unit (PACU) to the first administration of intravenous opioid will be recorded in minutes.

Within 24 hours postoperatively
Total Postoperative Tramadol Consumption
Tidsram: First 24 hours postoperatively

The total cumulative dose of intravenous opioid administered during the first 24 hours after surgery will be recorded.

First 24 hours postoperatively
Postoperative Nausea and Vomiting
Tidsram: Within 24 hours postoperatively

Postoperative nausea and vomiting (PONV) will be assessed using a 5-point Verbal Descriptive Scale (VDS), ranging from 0 to 4 (0 = no nausea or vomiting, 1 = mild nausea, 2 = moderate nausea or vomiting, 3 = frequent vomiting, and 4 = severe vomiting). Higher scores indicate more severe symptoms.

Within 24 hours postoperatively
Patient Satisfaction with Postoperative Analgesia
Tidsram: 24 hours postoperatively

Patient satisfaction with postoperative pain management will be assessed at 24 hours after surgery using a 5-point Likert scale ranging from 1 to 5. Higher scores indicate greater patient satisfaction with postoperative analgesia.

24 hours postoperatively

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

8 november 2026

Primärt slutförande (Beräknad)

8 februari 2027

Avslutad studie (Beräknad)

8 mars 2027

Studieregistreringsdatum

Först inskickad

11 november 2026

Först inskickad som uppfyllde QC-kriterierna

11 november 2026

Första postat (Faktisk)

18 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • KSH-QIPB-TLH-2026-01

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera